Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07630727 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of AHB-171 in Chronic Hepatitis B Participants

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 1 → 10 locationsv3
  2. Recruitment opened
    • Start date changed from estimate of Jul 15, 2026 to Jun 24, 2026
    • Secondary endpoints revised (22)
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study adopts an open-label, multiple-dose design and aims to evaluate the efficacy and safety of AHB-171 Injection after multiple doses in treatment-naïve (HBeAg-negative/positive) and nucleos(t)ide analogue (NA)-treated (HBeAg-negative) participants with chronic hepatitis B (CHB)
Trial Details
NCT Number NCT07630727
Lead Sponsor Ausper Biopharma Co., Ltd.
Conditions
(from sponsor)		 Hepatitis B, Chronic (CHB)
Related terms Bronchiolitis Obliterans Syndrome, Hepatitis B
Enrollment 138 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov